亚虹医药：在欧洲结直肠大会发布APL-1401 Ⅰb期临床试验数据

Core Viewpoint - Aihong Pharmaceutical (688176) announced the results of its APL-1401 clinical trial for moderate to severe active ulcerative colitis, which were presented at the 19th European Colorectal Congress [1] Group 1: Clinical Trial Information - APL-1401 is an innovative oral drug developed by the company, targeting autoimmune diseases with a novel mechanism of action [1] - The clinical trial is currently in the early stages, and there is uncertainty regarding whether the results will support a drug submission for market approval and when such approval might occur [1]